

Abstract
In the new ACR/EULAR APS classification criteria an entry criterion of at least one positive aPL test is included along with laboratory and clinical criteria, clustered into clinical and laboratory domains (Lupus Anticoagulant [LAC], and aCL and/or anti- β2glycoprotein-I (β2GPI) antibody IgG/M detected by ELISA). Patients accumulating at least three points from clinical and laboratory domains are classified as having APS. We discuss the mounting evidence that the epitope specificity of anti-β2GPI antibodies can offer additional diagnostic and prognostic information
| Pier-Luigi Meroni |
![]() |





